Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss since late April in order to transition patients off compounded drugs, or off-label versions of the medication, according to the news release.

By Rishika Sadam and Kashish Tandon HYDERABAD (Reuters) -Danish drugmaker Novo Nordisk launched its blockbuster weight-loss drug Wegovy in the world's most populous nation, in a move that will challenge rival Eli Lilly's Mounjaro,

Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell the weight-loss drug Wegovy. Novo Nordisk revealed on Monday that it will no longer work with Hims & Hers,